State of the Venture Capital Financing Market – Day 1
Paul Hastings LLP is hosting a 2-day series at MBC BioLabs on September 22, 2026 (1030 Brittan Ave, San Carlos) and September 23, 2026 (135 Mississippi St, SF).
Please join us for a discussion of the current state of the venture capital market financing and a Q&A session with VCs from the Bay Area life sciences community.
Moderator: James Huie, Paul Hastings LLP
Speakers:
Colin Walsh, PhD, Goldman Sachs Alternatives
Colin Walsh, PhD is a Managing Director and Senior Investor on the Life Sciences Investing team within Goldman Sachs Alternatives. Prior to joining the firm, Colin was a Partner at Qiming Venture Partners USA. He has more than ten years of experience working as an investor and operator in early-stage life sciences companies. Colin earned dual BS degrees in Chemical Engineering and Biochemistry from the University of Massachusetts, Amherst, and a PhD from the UC Berkeley-UCSF Graduate Program in Bioengineering.
Zach Collins, PhD, MBC Capital
Zach Collins, PhD is a Partner in Mission BioCapital’s San Francisco office. He focuses on investments in early-stage biopharmaceutical companies and launching early-stage company operations in collaboration with entrepreneurs at times through interim executive roles. He holds board roles at Cavalry Biosciences, Nuvig Therapeutics, Jupiter Bioventures, and additional early-stage portfolio companies. Zach served on the board of SiteOne Therapeutics through its 2025 acquisition by Eli Lilly for up to $1B. At MBC Biolabs, Zach supports startups as an Entrepreneur Success Partner. His training is in molecular biology & genetics. While at Harvard Medical School, Zach co-authored work that was recognized by Science as 2018’s Breakthrough of the Year. Zach holds a Ph.D. in Biological and Biomedical Sciences from Harvard University and a B.S. in Biology from George Washington University.
Alexis Ji, Primer Ventures
Dr. Alexis Ji is the Founding Partner of Primer Ventures, leveraging her two decades of expertise in research and investment in the biopharmaceutical and genomics industries. Primer Ventures is a venture capital firm investing in early-stage companies in the fields of life science tools and diagnostics, innovative therapeutics, and digital health. It provides early capital to empower visionary entrepreneurs in translating cutting-edge science and technologies into transformative products.
Hosted by:
